Pharmafile Logo

News and Press Releases

Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

5 November 2024 –Tokyo, Japan and London and Cardiff, UK – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio...

Category: BioManufacturing
Posted: November 6, 2024

Nxera Pharma
Midtown East 9-7-2 Akasaka Minato-ku Tokyo 107-0052

Antiverse raises £3.5M ($4.6M) to advance generative AI antibody design platform

Increases total equity financing raised to £7.2M ($10.1M) New facilities in Boston and Prague will provide increased capacity to deliver pipeline of pharma and biotech projects Funding to progress internal...

Category: Biotechnology, Drug Discovery
Posted: October 17, 2024

Antiverse
info@antiverse.io
MediCentre, Heath Park, Cardiff CF14 4UJ

Antiverse and GlobalBio, Inc extend collaboration to advance antibody cancer therapeutics

Collaboration successfully identified antibodies with therapeutic potential as checkpoint inhibitors in oncology Two antibodies showing high specificity for PD-1 are now being progressed to preclinical development Project leveraged Antiverse’s AI-driven...

Category: Biotechnology
Posted: October 16, 2023

Antiverse
info@antiverse.io
MediCentre, Heath Park, Cardiff CF14 4UJ